With over ten years of data on Cesium-131, researchers continue to study its value in powering modern brachytherapy. ASTRO 2020 showcased multiple new e-posters and papers that can now be easily accessed online. A Matched Pair Analysis Of Clinical Outcomes...
Dr. Peter Orio Showcases the Elegance and Simplicity of Brachytherapy for Prostate Cancer
Photo curtesy of The Boston Herald. Boston Herald Reporter Alexi Cohan recently joined Dr. Peter Orio on the “front lines” in order to learn more about brachytherapy for prostate cancer treatment. This article details the brachytherapy procedure process and the...
Study Shows Significantly Improved Survival Rate of Cervical Cancer Patients after Receiving Brachytherapy and EBRT
The International Journal of Radiation Oncology recently published a study titled Survival Benefit of Adjuvant Brachytherapy After Hysterectomy With Positive Surgical Margins in Cervical Cancer.
Biological effectiveness dose and convenience: Why Cesium-131 is the LDR brachytherapy isotope of choice for Dr. Bradley Prestidge.
Dr. Bradley Prestidge, MD, MS, serves as Regional Medical Director of Radiation Oncology for Bon Secours Medical Group in Norfolk, Va. During the American Brachytherapy Society 2018 Annual Meeting, Dr. Prestidge shared with us his opinion on brachytherapy’s top...
Our favorite prostate cancer support resources: 2018 edition
As the importance of patient involvement in determining their optimal post-treatment quality of life, these organizations educate and support the men and families affected by prostate cancer.
Dr. Brian J. Moran, Awareness in Action and Sky High Referral Rates
“Today, over 85% of our [low-dose rate brachytherapy] patients are referred from former, satisfied patients,” says Moran. Because of this, Dr. Moran recognizes the value of brachytherapy in the community and the awareness in action. Former patients have even a monthly support group meeting that Dr. Moran and his Director of Research and Education attend.
Newsweek: “Prostate cancer is often diagnosed too late.”
Prostate cancer is one of the deadliest and most common cancers among men today. An article written by Melissa Matthews was recently published by Newsweek revealing that late detection plays a key role in why prostate cancer is so fatal.
Dr. Brian Moran: Brachytherapy: An Innovative Disruptor
Dr. Brian Moran, Medical Director for the Chicago Prostate Center, discusses the value of low-dose rate brachytherapy and its disruptive innovation in the cancer treatment field at ABS 2018.
ABS 2018 Insights: Science, Improving Your Practice, Social Time & Thanks
With the 2018 edition of the American Brachytherapy Annual Meeting in the books, it is fitting to take a few minutes and highlight our top ABS 2018 Insights. The clinical experience with Cesium-131 continues to build: Dr. Manuj Agarwal of the University of Maryland...
Prostate Cancer News Today: “Prostate Cancer Patients Treated with Radioactive Seeds Retain Urinary, Bowel Quality”
“Prostate cancer patients treated with Cesium-131 brachytherapy maintained their urinary- and bowel-related quality of life years afterward, according to a recent study.” The study, “Long-term Quality of Life in Prostate Cancer Patients Treated with Cesium-131,” was...
Medpage Today: “EBRT with Brachytherapy Matches Surgery for Prostate Ca”
Worse survival without [brachytherapy] boost in high-risk patients At long last, the mounting scientific evidence for the value of brachytherapy for prostate cancer treatment is starting to generate more awareness among the care community and associated industry...
Sharpening the focus on focal therapy for prostate cancer treatment
To the benefit of patients and urologists worldwide, focal therapy for prostate cancer bridges the sizable gap between active surveillance and radical prostatectomy. Its ability to provide effective disease control, minimize the potential for chronic incontinence and...